Boothbay Fund Management LLC Acquires 71,543 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

Boothbay Fund Management LLC boosted its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 411.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 88,941 shares of the company's stock after purchasing an additional 71,543 shares during the period. Boothbay Fund Management LLC owned about 0.43% of Protara Therapeutics worth $470,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. HBK Investments L P bought a new position in shares of Protara Therapeutics in the fourth quarter worth about $106,000. Adage Capital Partners GP L.L.C. bought a new stake in Protara Therapeutics during the 4th quarter worth approximately $11,880,000. Dimensional Fund Advisors LP purchased a new position in Protara Therapeutics during the fourth quarter valued at approximately $111,000. Walleye Capital LLC bought a new position in shares of Protara Therapeutics in the fourth quarter worth approximately $1,166,000. Finally, Barclays PLC purchased a new stake in shares of Protara Therapeutics in the fourth quarter worth $492,000. Institutional investors own 38.13% of the company's stock.

Insider Buying and Selling at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the sale, the insider now owns 98,861 shares of the company's stock, valued at approximately $447,840.33. This represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.50% of the company's stock.

Protara Therapeutics Trading Down 0.3 %

NASDAQ TARA traded down $0.01 on Tuesday, reaching $3.38. The stock had a trading volume of 67,489 shares, compared to its average volume of 346,603. Protara Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $10.48. The company has a market capitalization of $130.40 million, a price-to-earnings ratio of -1.19 and a beta of 1.73. The business has a 50 day moving average price of $4.01 and a 200 day moving average price of $4.08.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.09. On average, analysts anticipate that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on TARA. Scotiabank started coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price objective on the stock. Lifesci Capital initiated coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a research report on Monday, April 28th. Finally, Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $20.40.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.